Drug resistance in multiple myeloma

Cancer Research Therapy and Control

Volumn 6, Issue 1-4, 1998, Pages 189-190

  Dalton, William S ^b   Grogan, Thomas ^b   Salmon, Sydney E ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACENE DERIVATIVE; CYCLOSPORIN A; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FAS ANTIGEN; GLYCOPROTEIN P; MELPHALAN; MITOXANTRONE; VERAPAMIL; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0032436897     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Shustik C, Dalton W. and Gros P. (1995). P-glycoprotein mediated multidrug resistance in tumor cells: biochemistry, clinical relevance, and modulation. Molec. Aspects Med., 16, 1-78, Great Britain: Elsevier Science Ltd.
2. Futscher B., Foley N., Gleason-Guzman M., Meltzer P., Sullivan D. and Dalton W.S. (1996). Verapamil suppresses the emergence of P-glycoprotein mediated multidrug resistance. Int. J. Cancer, 66, 520-525.
3. Abbaszedagan M., Foley N., Gleason-Guzman M. and Dalton W.S. (1996). Resistance to the chemosensitizer verapamil in a multidrug resistant (MDR) human multiple myeloma cell line. Int. J. Cancer, 66, 506-514.
4. Abbaszedagan M., Cress A.E., Futscher B., Bellamy W.T. and Dalton W.S. (1996). Evidence for Cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res., 56, 5435-5442.
5. Landowski T.H., Gleason-Guzman M.C. and Dalton W.S. (1997). Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89, 1854-1861.